Teva to Present at the BofA Securities Health Care Conference
Teva (NYSE: TEVA) announced that Eric Hughes, EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Health Care Conference on May 12, 2026 at 9:20 A.M.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Teva (NYSE: TEVA) announced that Eric Hughes, EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Health Care Conference on May 12, 2026 at 9:20 A.M. PT / 12:20 P.M. ET. Live webcasts will stream from Teva’s investor relations site; archived webcasts will appear within 24 hours and remain available for up to 30 days.
Details
News Market Reaction – TEVA
On May 5, the first trading day after this news, TEVA closed 1.44% above the previous close.
Data tracked by StockTitan Argus for the May 5 session.
Key Figures
- Q1 2026 revenue
- $3,982 million
- Three months ended March 31, 2026; up from $3,891M prior year
- Q1 2026 net income
- $369 million
- Up from $214M a year earlier
- Diluted EPS
- $0.31
- Quarter ended March 31, 2026; up from $0.18
- Cash & equivalents
- $3,741 million
- Balance as of March 31, 2026; increased versus prior year
- Senior notes and loans
- $14,015 million
- Total debt as of March 31, 2026
- Legal provisions
- $4,680 million
- Settlements and loss contingencies; includes $72M expense this quarter
- UZEDY net sales
- $63 million
- Q1 2026 U.S. net sales; up 62% YoY and 15% vs Q4 2025
- Emalex upfront payment
- $700 million
- Upfront consideration for Emalex acquisition plus up to $200M milestones
Historical Context
-
Highlighted ESG progress and sustainability-linked bond targets and access-to-medicine gains.
-
Reported strong UZEDY net sales growth and outlined associated royalty and milestone terms.
-
Delivered solid Q1 2026 results with growth from innovative brands and maintained outlook.
-
Announced Emalex acquisition, adding NDA-ready Tourette therapy to neuroscience pipeline.
-
Launched Home Ground™ schizophrenia community resource hub for patients and caregivers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time).
To access live webcasts of the presentations, please visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
Archived versions of the webcasts will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical Company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.